Company intelligence / Profile preview

Intelligent OMICS

Nottingham, England, United Kingdom

Ownership: Private
Development stage: Other

Overview

Intelligent OMICS (Intellomx) is an AI-driven biotech company providing preclinical discovery and in silico modeling services (target identification, virtual screening, digital twin off-target assessment, and companion diagnostics) to pharma and biotech partners; it does not publicly list proprietary clinical-stage drug assets and operates primarily as a discovery/platform and services company.[1][2][4][6]

Modalities: Small moleculeCompanion diagnostic
Industry: Drug Discovery Services

Partnerships

Janssen Research & Development (Johnson & Johnson) – target discovery in hematological malignancies[1]Several top‑100 global pharmaceutical companies (undisclosed) for early target identification and validation in oncology, neurology, infectious diseases and inflammatory disorders[1][6]

Beyond the preview

Go deeper on Intelligent OMICS.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Intelligent OMICS.

Explore the full profile